HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Valentina Guarneri(Istituto Oncologico Veneto), Aleix Prat(Hospital Clínic de Barcelona), Federica Miglietta(University of Padua), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), PierFranco Conte(University of Padua), Joel S. Parker(University of North Carolina at Chapel Hill), Charles M. Perou(University of North Carolina at Chapel Hill), Michele Bottosso(University of Padua), Mercedes Mar Ín-Aguilera(Oryzon Genomics (Spain)), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ana Vivancos(Vall d'Hebron Institute of Oncology), Patricia Villagrasa, Patricia Galv N(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Maria Vittoria Dieci(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Paula Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Cited by 42
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k